The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma-Reference-Cited by-同舟云学术

The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma

Published:2019-11-25 Issue:5 Volume:55 Page:946-954
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Tolomelli Giulia,Mancuso Katia,Tacchetti Paola,Patriarca Francesca,Galli Monica,Pantani Lucia,Zannetti Beatrice,Motta Maria Rosa,Rizzi Simonetta,Dan Elisa,Sinigaglia Barbara,Giudice Valeria,Olmo Andrea,Arpinati Mario,Chirumbolo Gabriella,Fanin Renato,Lewis Russell E.,Paris Laura,Bonifazi Francesca^ORCID,Cavo Michele,Curti Antonio,Lemoli Roberto M.

Funder

Plerixafor vials were provided by Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-019-0756-1.pdf

Reference45 articles.

1. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant. 2016;51:786–92.

2. Palumbo A, Cavallo F, Gay F, Raimondo Di, D BY F, Petrucci MT. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.

3. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–55.

4. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, et al. Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:967.

5. D’addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone marrow Transplant. 2011;46:356–63.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience;Transfusion and Apheresis Science;2021-06

2. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH);Transfusion and Apheresis Science;2021-04

3. Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector cell therapy;Current Opinion in Hematology;2020-09-14